Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avandia Advisory Cmte. Could Be Observational Data’s Coming Out Party

Executive Summary

The recommendations from FDA's joint advisory committee review of a signal of potential cardiovascular risk for GlaxoSmithKline's type 2 diabetes therapy Avandia (rosiglitazone) will likely be determined by how much weight the panel gives to meta-analysis as a means of assessing a drug's safety

You may also be interested in...



Advisory Cmte. Conflict of Interest Waivers Common; Avandia Is High Water Mark

As currently convened, the majority of FDA advisory committee meetings on drugs would likely violate a limit on participation by experts with a financial conflict of interest being considered by Congress

Advisory Cmte. Conflict of Interest Waivers Common; Avandia Is High Water Mark

As currently convened, the majority of FDA advisory committee meetings on drugs would likely violate a limit on participation by experts with a financial conflict of interest being considered by Congress

FDA Not Saying What House Democrats Want To Hear

Henry Waxman and House Democrats held an Oversight and Government Reform Committee meeting on GlaxoSmithKline's Avandia to highlight the need to stronger postmarketing oversight FDA.

Related Content

UsernamePublicRestriction

Register

PS048613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel